Iparomlimab/Tuvonralimab clinical trials
Also written QL1706 and PSB205.
How each study uses Iparomlimab/Tuvonralimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Iparomlimab/Tuvonralimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
118 studies that test it; most in 2025 (64); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 64 |
| 2026 | 33 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 97
Qilu Pharmaceutical Co., Ltd. (21) · Sun Yat-sen University (9) · Fudan University (8) · Tianjin Medical University Cancer Institute and Hospital (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Fujian Cancer Hospital (4) · Hebei Medical University Fourth Hospital (4) · Tongji Hospital (3)
Often tested with
Tested in the same studies.
Lenvatinib (10) · Bevacizumab (4) · Xelox (3) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Gemcitabine (2) · Fecal Microbiota Transplantation (2) · QLC5513 (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 40, 3 in phase 3
Studies that test Iparomlimab/Tuvonralimab, phase 3 first.
- Jun 2027INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell CarcinomaPhase 3 · Tongji Hospital
- Aug 2027A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Sep 2027A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaPhase 2/3 · Qilu Pharmaceutical Co., Ltd.
- Dec 2026QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract TumorsPhase 2 · Eastern Hepatobiliary Surgery Hospital
- Dec 2026Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal MetastasisPhase 1/2 · Guangzhou Medical University
- Dec 2026SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver MetastasesPhase 2 · Fujian Cancer Hospital
- Dec 2026Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisPhase 2 · Peking University Cancer Hospital & Institute
- Dec 2026Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerPhase 2 · Ruijin Hospital
- Feb 2027FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver MetastasisPhase 2 · Hua Jiang
- Feb 2027Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studies
Open first, then newest update. How each study uses Iparomlimab/Tuvonralimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 119
- A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingPhase 2Fujian Cancer HospitalNCT07940478Written as QL1706 (Iparomlimab/Tuvonralimab)
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07432594Written as Aitua Combination Antibody
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT07049185Written as QL1706 Plus Celecoxib Group
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCRecruitingPhase 2Guangdong Association of Clinical TrialsNCT07416058Written as QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Xijing HospitalNCT07876154Written as Iparomlimab/Tuvonralimab
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Ruijin HospitalNCT07867392Written as Iparomlimab and Tuvonralimab (QL1706)
- Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCCNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07847671Written as FMT combined with QL1706 plus Bevacizumab
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as QL1706
- Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With ChemotherapyRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07372079Written as QL1706 combined with Chemotherapy
- HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICCRecruitingPhase 2Lianghe LuNCT07841574Written as hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab
- FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver MetastasisRecruitingPhase 2Hua JiangNCT06801665Written as FMT+QL1706+Bevacizumab+XELOX
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Not yet recruitingPhase 2Fudan UniversityNCT07829874Written as QL1706 (Iparomlimab/Tuvonralimab)
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07828873Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruitingPhase 2Tongji HospitalNCT06954116Written as Iparomlimab and Tuvonralimab (QL1706)
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07776080Written as Iparomlimab and Tuvonralimab (QL1706)
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840Written as Iparomlimab and Tuvonralimab (QL1706)
- Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07179900Written as QL1706
- Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingPhase 2West China HospitalNCT07738159Written as Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC
- TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaRecruitingNot applicableFudan UniversityNCT07268131Written as TACE+QL1706
- QL1706(Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract CancerRecruitingPhase 2Shanghai Zhongshan HospitalNCT07733115Written as Iparomlimab and Tuvonralimab (QL1706)
See all 119 studies that test Iparomlimab/Tuvonralimab →
Given beside what is tested · 9 — Iparomlimab/Tuvonralimab is usual care or a partner of the new treatment
- A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaNot yet recruitingPhase 4Peking University Cancer Hospital & InstituteNCT07854522Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07646301Written as Iparomlimab and Tuvonralimab (QL1706)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal CancerNot yet recruitingPhase 2Huazhong University of Science and TechnologyNCT07502014Written as Iparomlimab and Tuvonralimab (QL1706)
- Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07407452Written as Iparomlimab and Tuvonralimab (QL1706)Injection
- A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07256782Written as QL1706
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCRecruitingPhase 1Xijing HospitalNCT07178171Written as QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian CancerNot yet recruitingPhase 2Fudan UniversityNCT07117877Written as Iparomlimab and Tuvonralimab (QL1706)
- A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)Not yet recruitingPhase 2Anhui Provincial HospitalNCT07128251Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingPhase 2Fudan UniversityNCT06786026Written as QL1706
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting3
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerNov 4, 2026NCT07432594
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaNov 2, 2026NCT07049185
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCOct 23, 2026NCT07416058
Newly registered2
- Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic CancerNov 16, 2026NCT07938658
- A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNov 16, 2026NCT07940478